Pharmaceuticals company Ajanta Pharma announced Q1FY25 results: Revenue from operations at Rs 1,145 crore against Rs 1,021 crore; up 12%. EBITDA at Rs 330 crore against Rs 271 crore; up 22%; EBITDA at 29%. Profit after tax at Rs 246 crore against Rs 208 crore; up 18%; PAT at 21%. Cashflow from operations (CFO) was Rs 466 crore, EBITDA to CFO conversion of 141%. Free cashflow (FCF) was Rs 301 crore, FCF to PAT conversion of 123%. Shareholders pay-out of Rs 351 crore in June 2024 through buyback of shares at a price of Rs 2,770 per equity share, constituting 0.82% of the total paid-up equity share capital. Result PDF
Pharmaceuticals company Ajanta Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from operations at Rs 1,054 crore against Rs 882 crore; up 20%. EBITDA at Rs 278 crore against Rs 149 crore; up 86%; EBITDA at 26%. Profit after tax at Rs 203 crore against Rs 122 crore; up 66%; PAT at 19%. FY24 Financial Highlights: Revenue from operations at Rs 4,209 crore against Rs 3,743 crore; up 12%. EBITDA at Rs 1,172 crore against Rs 783 crore; up 50%; EBITDA at 28%. Profit after tax at Rs 816 crore against Rs 588 crore; up 39%; PAT at 19%. Cashflow from operations (CFO) was Rs 785 crore, EBITDA to CFO conversion of 67%. Free cashflow (FCF) was Rs 637 crore, FCF to PAT conversion of 78%. Result PDF